Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(40%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
1
20%
Ph phase_4
2
40%

Phase Distribution

0

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution3 total trials
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
2(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(3)
Completed(1)
Other(1)

Detailed Status

Recruiting2
unknown1
Completed1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 31 (33.3%)
Phase 42 (66.7%)

Trials by Status

recruiting240%
unknown120%
completed120%
not_yet_recruiting120%

Recent Activity

2 active trials
Showing 5 of 5
recruiting

An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)

NCT06315556
recruitingphase_3

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

NCT05407636
not_yet_recruitingphase_4

Comparing Single Versus Multiple Anti-VEGF Injections in Diabetic Patients Undergoing Cataract Surgery

NCT07301775
completed

Real World Outcomes of Intravitreal Anti-vascular Endothelial Growth Factors for Neovascular Age Related Macular Degeneration in Taiwan

NCT03324542
unknownphase_4

Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration.

NCT01918878

Clinical Trials (5)

Showing 5 of 5 trials
NCT06315556

An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)

Recruiting
NCT05407636Phase 3

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

Recruiting
NCT07301775Phase 4

Comparing Single Versus Multiple Anti-VEGF Injections in Diabetic Patients Undergoing Cataract Surgery

Not Yet Recruiting
NCT03324542

Real World Outcomes of Intravitreal Anti-vascular Endothelial Growth Factors for Neovascular Age Related Macular Degeneration in Taiwan

Completed
NCT01918878Phase 4

Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration.

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5